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Fabrication of multifunctional ultrasound contrast agents (UCAs) have been recently addressed in several 
research groups. A versatile strategy for the synthesis of UCAs precursors in the form of biodegradable 
vesicles with a crosslinked biocompatible polymer is described. Upon ultrasound irradiation, acoustic 
droplet evaporation transforms such particles into microbubbles behaving as UCAs. This proof of concept 
entails the features of a potential theranostic microdevice.  
The use of contrast media in medical imaging is increasing and new or revised devices are designed to 
implement their functionality. Microbubbles (MBs) are used as ultrasound contrast agent (UCA).1 They are 
micron-sized systems consisting of a gas core stabilized by a lipid or polymeric shell. Advantages and 
disadvantages are present in the use of both types.2 Lipid shelled MBs scatter ultrasound efficiently but, 
once injected, their life in the blood pool is quite short and their dimensions are characterized by a broad 
distribution. Chemical modifications of the lipid layer have been attempted in order to target MBs to 
pathological tissues or cells.3 Polymer shelled MBs are more stable.4 However, their shell is less elastic 
than the lipidic ones, causing a lower echogenicity. The robustness of their shell is an asset if extensive 
chemical modifications are planned to enable multimodal imaging in combination with targeting and drug 
delivery capabilities. Surface decoration represents a step further toward the design of a truly theranostic 
device.5 
Design of multimodal contrast agents, enabling a limited number of functionalities can be easily found in 
the literature.6 Recently, Rapoport7 described the method for depositing a polymer layer using a PFC-in-
water miniemulsion stabilized by an amphiphilic co-polymer. To obtain polymer shelled nanocapsules, 
Cavalli8 layered chitosan on perfluorocarbon nanodroplets stabilized by the presence of an emulsifying 
agent.  
In this paper we describe a general, robust strategy for the obtainment of MBs with different crosslinked 
polymer shells. Fig. 1 shows a schematic representation of the assembly process involving (i) the deposition 
of a shell of a surfactant layer, around a PFC, typically decafluoropentane, droplet in water; (ii) the 
deposition, as outmost layer on the water/vesicle interface, of a hydrophilic polymer grafted with a vinyl 
moiety, driven by the ability of the vinyl residues to stick in the vesicle shell; (iii) the free radical 
photopolymerization to crosslink the grafted vinyl side-chains. The interfacial properties of PFCs are unique 
and the use of these compounds can be advantageously exploited for pharmaceutical formulations.1,9,10 
Polysaccharides bearing hydrophobic methacrylate side chains spontaneously accommodate on top of the 
surfactant shell to form the outer polymer layer.  
  
 
 Fig. 1 Schematic representation of polymer shelled vesicles. 
 
The polymerization is then triggered by a photoinitiator and the polysaccharide shell is crosslinked around 
the PFC liquid core. These vesicles, irradiated by ultrasound (US), can undergo an acoustic droplet 
vaporization, ADV,11 which allows a liquid  gas transition in the core, transforming the polymer vesicles 
into MBs. This process is readily observed by the floating tendency of the MBs and can be monitored by 
laser scanning confocal microscopy (CLSM), coupling rhodamine B isothiocianate, RBITC, on the polymer 
shells. In CLSM images the vesicles/microbubbles are described as rings after focusing the equatorial plane 
of fluorescent labelled shells.   
As candidates for the fabrication of the shell, we have explored the properties of methacryloyl-grafted 
dextran and hyaluronic acid. Both polysaccharides are biodegradable12 and their degree of substitution, 
DS, is 50 and 30 % (mol/mol), respectively. These polymers will be named hereafter DexMA50 and 
HAMA30, respectively. Methacrylic moiety is readily photopolymerized in emulsion, forming 
poly(methacrylic), pMA, chains. In this way the grafted polymers are crosslinked in a network constituting 
the shell of the vesicle.13 
The synthesis of such derivatives and that of the polymer shelled vesicles are reported in the supporting 
information. Fig. 2 highlights the behaviour of DexMA50 vesicles upon treatment with US with 
characteristics reported in the supporting information.  
 
  
Fig. 2 Confocal microscopy of DexMA50 shelled vesicles (a) before US irradiation, (b) after US irradiation 
and (c) one hour after US irradiation. Insets: size distributions and mean diameters. 
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Before US irradiation (Fig. 2, a), the vesicles sink in water because of the higher density of the liquid 
decafluoropentane core. Their average diameter is 5 μm. After US irradiation (Fig. 2, b), the energy 
provided under the form of ultrasound mechanical waves enables the transition of the liquid PFC to gas and 
the passage from vesicles to MBs with a marked increase of the average diameter of about 5 μm. Once the 
energy has been dissipated (Fig. 2, c), the MBs revert to vesicles recovering the original diameter. In an 
ideal bubble, with infinitely thin shell having a surface tension σ and a radius r, the inside pressure, Pin, is 
equal to the outside pressure, Pout, increased by the Laplace pressure term: 
 
The boiling point of decafluoropentane at standard pressure is 55 °C with a vaporization enthalpy of 6816 
cal/mol.14 The additional Laplace term increases the boiling point of the liquid core well above the 
physiological temperature.15 The action of the US is key for the vaporization and it is showed in DexMA50 
MBs by a 100 % of increase in the system dimensions. This change depends on the polymer elasticity and 
on the crosslinking degree of the shell. The reported behaviour opens a future perspective in the 
exploitation of the vesicle  microbubble transition for a combined imaging and therapeutic approach. The 
liquid hydrophobic core can be regarded as a drug reservoir to be targeted in the vicinity of the pathological 
tissue and, via US driven ADV, simultaneously allowing the sonographic imaging. MBs can be blasted, if 
properly excited by US, to release the drug payload. The US conditions in which DexMA50 MBs can be 
destroyed in an in vitro experiment is reported in supporting information. 
DexMA50 MBs echogenicity was tested in an in vitro experiment using either 18 or 24 MHz transducers of a 
Vevo2100 (VisualSonics Inc.) instrument, which provides high resolution imaging down to 30 microns and 
non-linear image analysis. Two acquisition modalities are captured: traditional B - mode and non-linear 
contrast modality.16 
 
 
 
 
 
 
 
 
Figure 3 – DexMA50 MBs images acquired with the Vevo 2100 system using a 18 MHz probe and power 
level set to 100%. Top: non-linear mode. Bottom: traditional B-Mode. The red lines help to identify the 
inner walls of the silicon tubes.  
 
The experimental details are described in the supporting information. A good echogenicity is found (Fig. 3). 
MBs are clearly visible in the tube lumen, with more intense echo signals in the non-linear image modality. 
The peak of negative pressure value at which ADV transition occurs is about 1 MPa, according to a 
harmonic analysis, is shown in Figure 4. 1MPa corresponds to a mechanical index, MI, of 0.67, a value well 
below 1.9 indicated as the safety limit of medical ultrasound scanners. Experimental details are reported in 
supporting information. 
  
Fig. 4 Second (A) and third (B) harmonic amplitude as a function of applied  negative pressure. 
 
The biodegradation is a key issue for the drug delivery and for assessing the bioelimination pathways, 
usually involving spleen or liver. Fig. 5 shows that dextran shelled MBs are degraded by the catalytic action 
of lysozyme. In the presence of a more specific enzyme such as dextranase, the degradation time is much 
shorter (see supporting information for details). 
  
Fig. 5 Lysozyme catalysed degradation of DexMA50 vesicles.  
 
To demonstrate the effective versatility of this synthetic route, an additional vinyl monomer, N-
isopropylacrylamide (NiPAAm), was added to the MB shells and co-polymerized with the methacrylic 
sidechains of the grafted dextran. In this case, dextran chains are crosslinked by poly(methacrylate-co-
NiPAAm) co-polymer chains, with the inclusion in the shell of random sequences of NiPAAm. This residue is 
often used as co-monomer to add thermal responsivity to a polymer due to the lower critical solution 
temperature (LCST) present in oligomers and polymers.17 Vesicles shells containing dextran crosslinked to 
p(methacrylate-co-NiPAAm), dex/p(MA-co-NiPAAm), have a thermoresponsive behaviour, as highlighted in 
Fig. 6. 
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When the temperature is increased from 25 to 45 °C, the fluorescence of dex/p(MA-co-NiPAAm) vesicles is 
quenched almost completely. On cooling back to RT, the vesicles emit fluorescence as in the starting 
conditions, indicating the absence of MB degradation occurring during the heating step. In a control 
experiment, DexMA50 shelled vesicles do not show a fluorescence quenching when heated at 45 °C (Fig. 6, 
b’). 
  
Fig. 6 Thermal behaviour of dextran based vesicles: dex/p(MA-co-NiPAAm) shelled vesicles. (a) at room 
temperature (RT); (b) at 45 °C; (c) back at RT; DexMA50 shelled vesicles (d) at RT; (e) at 45 °C and (f) back at 
RT. 
 
We hypothesize that the quenching of fluorescence in the NiPAAm containing vesicles at 45 °C is due to an 
LCST effect localized in the vesicle shells, which shields the fluorophore from the incident light decreasing 
substantially the fluorescence emission.18  
With small changes with respect to the synthesis of DexMA50 vesicles, vesicles can be fabricated with 
methacrylate derivative of hyaluronic acid having a degree of substitution of 30 %, HAMA30. The droplets 
of liquid PFC were stabilized with Pluronic 127 and octylamine as co-surfactant. Details of the synthesis are 
reported in the supporting information. The positive charges on octylamine favour the deposition of 
HAMA30 on the surface of the surfactant layer. The behaviour upon US irradiation is quite similar to what 
found for DexMA50 MBs. The increase in the diameter following US irradiation is about 100 % (see Figure 
7). 
  
Fig. 7 Confocal microscopy of HAMA30 shelled vesicles (a) before US irradiation, (b) after US irradiation and 
(c) one hour after US irradiation. Insets: size distributions and mean diameters. 
Conclusions 
We have presented a new class of core-shell microsystems based on biodegradable crosslinked polymers 
with features that can be exploited for the design of a multifunctional device. The micron size of these 
vesicles makes easier the ADV as compared to nanovesicles, allowing an easy US visualization. This unique 
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set of properties can be exploited for the design of a theranostic device with a potential huge impact on 
multimodality imaging and anticancer therapy. Moreover, peak negative pressure threshold values 
necessary to allow US imaging are compatible with the safety limits suggested by medical directories.    
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